 Kristen Nadeau
Concepts (501)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 70 | 2024 | 1077 | 10.950 |
Why?
| | Diabetes Mellitus, Type 2 | 79 | 2024 | 2098 | 8.470 |
Why?
| | Diabetes Mellitus, Type 1 | 51 | 2023 | 3245 | 5.620 |
Why?
| | Metformin | 20 | 2023 | 278 | 4.360 |
Why?
| | Obesity | 37 | 2023 | 2524 | 4.150 |
Why?
| | Pediatric Obesity | 21 | 2023 | 492 | 3.750 |
Why?
| | Blood Glucose | 52 | 2023 | 1821 | 3.680 |
Why?
| | Polycystic Ovary Syndrome | 15 | 2022 | 141 | 3.620 |
Why?
| | Diabetic Nephropathies | 14 | 2022 | 234 | 3.440 |
Why?
| | Adolescent | 153 | 2024 | 17864 | 3.430 |
Why?
| | Hypoglycemic Agents | 24 | 2023 | 1006 | 3.380 |
Why?
| | Prediabetic State | 12 | 2022 | 224 | 2.350 |
Why?
| | Hyperglycemia | 6 | 2022 | 293 | 2.230 |
Why?
| | Glucose Tolerance Test | 25 | 2023 | 344 | 2.130 |
Why?
| | Cardiovascular Diseases | 22 | 2023 | 1729 | 2.100 |
Why?
| | Glucose Clamp Technique | 17 | 2021 | 181 | 2.060 |
Why?
| | Insulin | 30 | 2024 | 2082 | 2.060 |
Why?
| | Child | 97 | 2023 | 18407 | 2.020 |
Why?
| | Diabetes Mellitus | 8 | 2023 | 906 | 1.920 |
Why?
| | Mitochondria, Muscle | 6 | 2019 | 93 | 1.820 |
Why?
| | Adipose Tissue | 7 | 2021 | 558 | 1.730 |
Why?
| | Young Adult | 57 | 2024 | 10498 | 1.690 |
Why?
| | Fatty Liver | 7 | 2021 | 217 | 1.630 |
Why?
| | Overweight | 6 | 2023 | 474 | 1.590 |
Why?
| | Puberty | 8 | 2021 | 137 | 1.590 |
Why?
| | Vascular Stiffness | 7 | 2023 | 408 | 1.580 |
Why?
| | Female | 127 | 2024 | 59617 | 1.560 |
Why?
| | Insulin-Secreting Cells | 8 | 2021 | 318 | 1.520 |
Why?
| | Cystic Fibrosis | 8 | 2023 | 957 | 1.500 |
Why?
| | Humans | 178 | 2024 | 115047 | 1.500 |
Why?
| | Exercise Tolerance | 5 | 2017 | 213 | 1.450 |
Why?
| | Obesity, Morbid | 4 | 2021 | 198 | 1.450 |
Why?
| | Male | 105 | 2024 | 55735 | 1.390 |
Why?
| | Fructosamine | 4 | 2019 | 14 | 1.370 |
Why?
| | Body Mass Index | 26 | 2023 | 1967 | 1.370 |
Why?
| | Fatty Acids, Nonesterified | 6 | 2018 | 151 | 1.350 |
Why?
| | Glucose Intolerance | 9 | 2022 | 137 | 1.300 |
Why?
| | Serum Albumin | 4 | 2019 | 134 | 1.290 |
Why?
| | Biomarkers | 21 | 2022 | 3419 | 1.270 |
Why?
| | Circadian Rhythm | 5 | 2022 | 354 | 1.260 |
Why?
| | Muscle, Skeletal | 9 | 2019 | 1477 | 1.240 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2020 | 34 | 1.220 |
Why?
| | Deoxyglucose | 3 | 2019 | 43 | 1.210 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 469 | 1.090 |
Why?
| | Adiposity | 6 | 2020 | 466 | 1.090 |
Why?
| | Triglycerides | 11 | 2022 | 471 | 1.070 |
Why?
| | Adiponectin | 4 | 2016 | 212 | 1.060 |
Why?
| | Diabetes Complications | 4 | 2023 | 212 | 1.050 |
Why?
| | Diabetic Angiopathies | 7 | 2020 | 244 | 1.030 |
Why?
| | Sleep | 9 | 2022 | 631 | 1.020 |
Why?
| | Bariatric Surgery | 4 | 2020 | 162 | 1.020 |
Why?
| | Leptin | 3 | 2023 | 211 | 1.000 |
Why?
| | Oxygen Consumption | 7 | 2018 | 588 | 0.990 |
Why?
| | Case-Control Studies | 17 | 2022 | 3015 | 0.930 |
Why?
| | Glomerular Filtration Rate | 12 | 2024 | 604 | 0.920 |
Why?
| | Diabetes, Gestational | 4 | 2023 | 281 | 0.920 |
Why?
| | Lipid Metabolism | 6 | 2020 | 449 | 0.910 |
Why?
| | Body Composition | 9 | 2021 | 586 | 0.880 |
Why?
| | Testosterone | 5 | 2020 | 343 | 0.870 |
Why?
| | Lipids | 7 | 2022 | 586 | 0.860 |
Why?
| | Risk Factors | 29 | 2022 | 8642 | 0.840 |
Why?
| | Exercise | 13 | 2023 | 1644 | 0.830 |
Why?
| | Metabolic Syndrome | 7 | 2020 | 324 | 0.810 |
Why?
| | Cross-Sectional Studies | 25 | 2021 | 4411 | 0.800 |
Why?
| | Glycopeptides | 2 | 2021 | 43 | 0.770 |
Why?
| | Adult | 42 | 2024 | 30658 | 0.770 |
Why?
| | Lipolysis | 3 | 2018 | 39 | 0.770 |
Why?
| | Fatty Acids | 2 | 2019 | 385 | 0.760 |
Why?
| | Weight Reduction Programs | 2 | 2019 | 94 | 0.760 |
Why?
| | Mass Screening | 7 | 2022 | 1012 | 0.760 |
Why?
| | Fasting | 5 | 2022 | 242 | 0.730 |
Why?
| | Kidney | 8 | 2024 | 1186 | 0.720 |
Why?
| | Liver | 6 | 2019 | 1681 | 0.720 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2021 | 96 | 0.720 |
Why?
| | Hyperinsulinism | 2 | 2019 | 103 | 0.720 |
Why?
| | Gastric Bypass | 1 | 2021 | 93 | 0.690 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 249 | 0.680 |
Why?
| | Creatinine | 7 | 2022 | 425 | 0.680 |
Why?
| | Inservice Training | 1 | 2020 | 107 | 0.670 |
Why?
| | Pulse Wave Analysis | 7 | 2023 | 208 | 0.660 |
Why?
| | Aorta | 2 | 2019 | 389 | 0.660 |
Why?
| | Uromodulin | 1 | 2019 | 21 | 0.650 |
Why?
| | Oxidative Phosphorylation | 3 | 2018 | 156 | 0.640 |
Why?
| | Endocrinology | 1 | 2020 | 69 | 0.640 |
Why?
| | Myocardial Contraction | 1 | 2020 | 313 | 0.630 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 38 | 0.630 |
Why?
| | Mentors | 1 | 2020 | 158 | 0.630 |
Why?
| | Mentoring | 1 | 2020 | 101 | 0.620 |
Why?
| | Lipogenesis | 3 | 2019 | 57 | 0.610 |
Why?
| | Non-alcoholic Fatty Liver Disease | 5 | 2021 | 246 | 0.610 |
Why?
| | Alaska Natives | 1 | 2020 | 117 | 0.610 |
Why?
| | Sex Characteristics | 6 | 2022 | 635 | 0.610 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 119 | 0.610 |
Why?
| | Interprofessional Relations | 1 | 2020 | 251 | 0.600 |
Why?
| | Glucose | 9 | 2023 | 900 | 0.600 |
Why?
| | Life Style | 6 | 2019 | 431 | 0.600 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 523 | 0.580 |
Why?
| | Child Behavior | 1 | 2019 | 219 | 0.570 |
Why?
| | Affect | 1 | 2019 | 246 | 0.570 |
Why?
| | Blood Vessels | 1 | 2018 | 180 | 0.570 |
Why?
| | Hypoglycemia | 2 | 2023 | 385 | 0.560 |
Why?
| | Double-Blind Method | 6 | 2022 | 1665 | 0.560 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 232 | 0.560 |
Why?
| | Peptide Fragments | 1 | 2021 | 668 | 0.560 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2017 | 482 | 0.550 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 361 | 0.550 |
Why?
| | Human Development | 1 | 2016 | 14 | 0.550 |
Why?
| | Amino Acids | 2 | 2022 | 451 | 0.540 |
Why?
| | Echocardiography | 3 | 2020 | 557 | 0.540 |
Why?
| | Lipoproteins | 2 | 2022 | 160 | 0.520 |
Why?
| | Schools | 1 | 2018 | 400 | 0.510 |
Why?
| | Thinness | 2 | 2013 | 87 | 0.500 |
Why?
| | Hyperandrogenism | 1 | 2015 | 14 | 0.490 |
Why?
| | Cohort Studies | 14 | 2021 | 4904 | 0.470 |
Why?
| | Albuminuria | 4 | 2022 | 164 | 0.450 |
Why?
| | Hemodynamics | 4 | 2022 | 1017 | 0.450 |
Why?
| | Indians, North American | 4 | 2023 | 570 | 0.450 |
Why?
| | Glycation End Products, Advanced | 4 | 2019 | 57 | 0.440 |
Why?
| | Actigraphy | 4 | 2022 | 74 | 0.440 |
Why?
| | Follow-Up Studies | 11 | 2020 | 4420 | 0.430 |
Why?
| | Treatment Outcome | 10 | 2021 | 9123 | 0.430 |
Why?
| | Cardiovascular System | 2 | 2012 | 126 | 0.430 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2021 | 194 | 0.430 |
Why?
| | Absorptiometry, Photon | 3 | 2019 | 223 | 0.430 |
Why?
| | Pediatrics | 2 | 2020 | 981 | 0.420 |
Why?
| | Risk Reduction Behavior | 4 | 2023 | 201 | 0.410 |
Why?
| | Prognosis | 10 | 2020 | 3334 | 0.410 |
Why?
| | Intra-Abdominal Fat | 3 | 2019 | 83 | 0.410 |
Why?
| | Age of Onset | 4 | 2020 | 449 | 0.390 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 3 | 2007 | 54 | 0.390 |
Why?
| | Islets of Langerhans | 2 | 2021 | 729 | 0.390 |
Why?
| | Lung Diseases | 1 | 2018 | 703 | 0.380 |
Why?
| | Prospective Studies | 8 | 2022 | 6232 | 0.370 |
Why?
| | Uric Acid | 4 | 2021 | 148 | 0.370 |
Why?
| | Hypogonadism | 1 | 2010 | 75 | 0.350 |
Why?
| | Pilot Projects | 5 | 2021 | 1375 | 0.350 |
Why?
| | Comorbidity | 3 | 2013 | 1457 | 0.350 |
Why?
| | Cholesterol, LDL | 5 | 2018 | 307 | 0.350 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 486 | 0.350 |
Why?
| | Diabetic Ketoacidosis | 2 | 2022 | 159 | 0.340 |
Why?
| | Preventive Health Services | 1 | 2011 | 135 | 0.340 |
Why?
| | Delivery of Health Care | 1 | 2016 | 835 | 0.330 |
Why?
| | Sex Factors | 6 | 2019 | 1721 | 0.330 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2023 | 497 | 0.320 |
Why?
| | Disease Progression | 8 | 2022 | 2389 | 0.320 |
Why?
| | Alanine Transaminase | 2 | 2008 | 140 | 0.310 |
Why?
| | Hypolipidemic Agents | 3 | 2020 | 87 | 0.310 |
Why?
| | Prevalence | 6 | 2021 | 2255 | 0.300 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2020 | 117 | 0.300 |
Why?
| | C-Peptide | 3 | 2020 | 138 | 0.300 |
Why?
| | Reproducibility of Results | 5 | 2021 | 2799 | 0.300 |
Why?
| | Cholesterol, HDL | 6 | 2021 | 184 | 0.290 |
Why?
| | Linear Models | 4 | 2019 | 776 | 0.280 |
Why?
| | Oxygen | 3 | 2024 | 854 | 0.280 |
Why?
| | Minority Groups | 2 | 2020 | 228 | 0.280 |
Why?
| | Cardiorespiratory Fitness | 2 | 2017 | 35 | 0.270 |
Why?
| | Colorado | 9 | 2020 | 4089 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 6 | 2021 | 3118 | 0.270 |
Why?
| | Health Status | 1 | 2011 | 722 | 0.270 |
Why?
| | Food Deprivation | 1 | 2006 | 24 | 0.260 |
Why?
| | Bromocriptine | 2 | 2022 | 26 | 0.260 |
Why?
| | United States | 11 | 2021 | 12227 | 0.260 |
Why?
| | Gastrointestinal Microbiome | 3 | 2021 | 502 | 0.260 |
Why?
| | Diastole | 3 | 2022 | 131 | 0.250 |
Why?
| | Blood Pressure | 6 | 2019 | 1539 | 0.250 |
Why?
| | Age Factors | 8 | 2021 | 2894 | 0.250 |
Why?
| | Reproductive Health | 2 | 2023 | 70 | 0.250 |
Why?
| | Body Fat Distribution | 2 | 2019 | 44 | 0.250 |
Why?
| | Early Medical Intervention | 2 | 2018 | 51 | 0.240 |
Why?
| | Cystatin C | 2 | 2014 | 62 | 0.240 |
Why?
| | Risk Assessment | 5 | 2022 | 2976 | 0.240 |
Why?
| | 3T3-L1 Cells | 1 | 2004 | 31 | 0.240 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 34 | 0.230 |
Why?
| | Quality of Life | 2 | 2014 | 2359 | 0.230 |
Why?
| | Cross-Over Studies | 2 | 2022 | 441 | 0.230 |
Why?
| | Aging | 1 | 2014 | 1624 | 0.230 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 196 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1215 | 0.220 |
Why?
| | Predictive Value of Tests | 4 | 2018 | 1812 | 0.220 |
Why?
| | Body Weight | 3 | 2020 | 873 | 0.220 |
Why?
| | Oral Health | 2 | 2015 | 138 | 0.220 |
Why?
| | Muscles | 1 | 2004 | 324 | 0.210 |
Why?
| | Hyperoxia | 1 | 2024 | 99 | 0.210 |
Why?
| | Time Factors | 7 | 2022 | 6141 | 0.210 |
Why?
| | Hepatitis | 1 | 2003 | 45 | 0.210 |
Why?
| | Adipocytes | 1 | 2004 | 189 | 0.210 |
Why?
| | Gastroplasty | 1 | 2022 | 26 | 0.200 |
Why?
| | Mucous Membrane | 1 | 2023 | 108 | 0.200 |
Why?
| | Systole | 2 | 2020 | 171 | 0.200 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 48 | 0.200 |
Why?
| | Waist Circumference | 4 | 2020 | 123 | 0.200 |
Why?
| | Mother-Child Relations | 1 | 2023 | 111 | 0.200 |
Why?
| | Disease Management | 2 | 2016 | 563 | 0.190 |
Why?
| | Pregnancy | 6 | 2023 | 5520 | 0.190 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2551 | 0.190 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 65 | 0.190 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 100 | 0.190 |
Why?
| | Melatonin | 2 | 2019 | 105 | 0.190 |
Why?
| | Lipoproteins, HDL | 2 | 2021 | 76 | 0.190 |
Why?
| | Healthy Volunteers | 1 | 2022 | 197 | 0.190 |
Why?
| | Eating | 2 | 2021 | 347 | 0.190 |
Why?
| | Kidney Tubules | 1 | 2021 | 107 | 0.180 |
Why?
| | Accelerometry | 1 | 2021 | 73 | 0.180 |
Why?
| | Adolescent Behavior | 2 | 2017 | 488 | 0.180 |
Why?
| | Exercise Test | 2 | 2016 | 545 | 0.180 |
Why?
| | Renal Insufficiency | 1 | 2022 | 136 | 0.180 |
Why?
| | Weight Gain | 2 | 2021 | 451 | 0.180 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 20 | 0.170 |
Why?
| | Risk | 3 | 2017 | 815 | 0.170 |
Why?
| | Precision Medicine | 3 | 2023 | 340 | 0.170 |
Why?
| | Middle Aged | 11 | 2022 | 26830 | 0.170 |
Why?
| | Physicians, Women | 1 | 2020 | 55 | 0.170 |
Why?
| | Dental Caries | 1 | 2021 | 160 | 0.170 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 50 | 0.170 |
Why?
| | Glycerol | 2 | 2019 | 84 | 0.170 |
Why?
| | Longitudinal Studies | 5 | 2023 | 2389 | 0.170 |
Why?
| | Exercise Therapy | 3 | 2019 | 351 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 955 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 719 | 0.160 |
Why?
| | Estradiol | 2 | 2019 | 455 | 0.160 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 37 | 0.160 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2020 | 175 | 0.160 |
Why?
| | Gluconeogenesis | 1 | 2019 | 62 | 0.160 |
Why?
| | Calorimetry, Indirect | 1 | 2019 | 70 | 0.160 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 71 | 0.160 |
Why?
| | Peer Group | 1 | 2020 | 203 | 0.160 |
Why?
| | Sleep Deprivation | 1 | 2021 | 166 | 0.160 |
Why?
| | Carnitine | 1 | 2019 | 62 | 0.160 |
Why?
| | Career Choice | 1 | 2020 | 181 | 0.150 |
Why?
| | Glucagon | 2 | 2023 | 93 | 0.150 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 124 | 0.150 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1081 | 0.150 |
Why?
| | Universities | 1 | 2020 | 339 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| | Aminopyridines | 1 | 2018 | 81 | 0.150 |
Why?
| | Sugars | 1 | 2018 | 29 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2021 | 12548 | 0.150 |
Why?
| | Social Media | 1 | 2020 | 133 | 0.150 |
Why?
| | Peptides | 1 | 2023 | 849 | 0.150 |
Why?
| | Benzodioxoles | 1 | 2018 | 83 | 0.150 |
Why?
| | Acute Kidney Injury | 2 | 2021 | 638 | 0.150 |
Why?
| | Fructose | 1 | 2018 | 100 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2020 | 256 | 0.150 |
Why?
| | Autoimmunity | 2 | 2021 | 818 | 0.150 |
Why?
| | Transgender Persons | 1 | 2020 | 134 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1318 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 333 | 0.140 |
Why?
| | Quinolones | 1 | 2018 | 97 | 0.140 |
Why?
| | Aminophenols | 1 | 2018 | 112 | 0.140 |
Why?
| | Adenosine Diphosphate | 1 | 2017 | 81 | 0.140 |
Why?
| | Biodiversity | 1 | 2020 | 358 | 0.140 |
Why?
| | Depression | 3 | 2023 | 1136 | 0.140 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 236 | 0.140 |
Why?
| | Social Support | 1 | 2020 | 528 | 0.140 |
Why?
| | Allostasis | 1 | 2016 | 12 | 0.140 |
Why?
| | Societies, Medical | 1 | 2020 | 678 | 0.140 |
Why?
| | Nutrition Surveys | 1 | 2017 | 224 | 0.130 |
Why?
| | Transcription Factors | 1 | 2004 | 1531 | 0.130 |
Why?
| | Diet Therapy | 1 | 2016 | 36 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2018 | 154 | 0.130 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1747 | 0.130 |
Why?
| | Area Under Curve | 1 | 2016 | 275 | 0.130 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 80 | 0.130 |
Why?
| | Metabolome | 1 | 2019 | 285 | 0.130 |
Why?
| | Child, Preschool | 7 | 2021 | 9093 | 0.130 |
Why?
| | Pandemics | 2 | 2022 | 1322 | 0.130 |
Why?
| | Energy Metabolism | 1 | 2021 | 729 | 0.130 |
Why?
| | Muscle Strength | 2 | 2017 | 271 | 0.130 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 92 | 0.130 |
Why?
| | Algorithms | 3 | 2021 | 1489 | 0.130 |
Why?
| | Weight Loss | 4 | 2022 | 641 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Androgens | 1 | 2016 | 167 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 930 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2016 | 428 | 0.120 |
Why?
| | Pregnancy in Diabetics | 1 | 2015 | 82 | 0.120 |
Why?
| | Bone Density | 1 | 2018 | 432 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2016 | 201 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2018 | 458 | 0.120 |
Why?
| | Child Health | 1 | 2015 | 126 | 0.120 |
Why?
| | Phosphorus | 1 | 2014 | 81 | 0.120 |
Why?
| | Metabolomics | 1 | 2019 | 527 | 0.120 |
Why?
| | Hypoxia | 1 | 2020 | 959 | 0.120 |
Why?
| | Stress, Mechanical | 1 | 2016 | 447 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 728 | 0.110 |
Why?
| | Consensus | 1 | 2016 | 534 | 0.110 |
Why?
| | Autoantibodies | 1 | 2021 | 1354 | 0.110 |
Why?
| | Pregnancy Outcome | 1 | 2015 | 337 | 0.110 |
Why?
| | Animals | 8 | 2018 | 31867 | 0.110 |
Why?
| | Health Literacy | 1 | 2015 | 166 | 0.110 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 675 | 0.110 |
Why?
| | Drug Combinations | 3 | 2019 | 287 | 0.110 |
Why?
| | American Heart Association | 1 | 2014 | 264 | 0.110 |
Why?
| | Adolescent Health Services | 1 | 2013 | 68 | 0.100 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 17 | 0.100 |
Why?
| | Blotting, Western | 2 | 2006 | 1149 | 0.100 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 185 | 0.100 |
Why?
| | Histidine | 2 | 2022 | 57 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 772 | 0.100 |
Why?
| | Muscle Cells | 1 | 2012 | 42 | 0.100 |
Why?
| | Self Care | 1 | 2014 | 351 | 0.100 |
Why?
| | Rats | 4 | 2011 | 4973 | 0.100 |
Why?
| | Health Behavior | 1 | 2017 | 704 | 0.100 |
Why?
| | Muscle Contraction | 1 | 2014 | 399 | 0.100 |
Why?
| | Medication Adherence | 1 | 2016 | 537 | 0.100 |
Why?
| | Heart Ventricles | 1 | 2016 | 714 | 0.100 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 44 | 0.090 |
Why?
| | Hypertension | 1 | 2019 | 1058 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1435 | 0.090 |
Why?
| | Matrix Metalloproteinases | 1 | 2011 | 89 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 676 | 0.090 |
Why?
| | Phenotype | 2 | 2022 | 2815 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 162 | 0.090 |
Why?
| | Models, Biological | 1 | 2017 | 1636 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1398 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2014 | 682 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 281 | 0.080 |
Why?
| | Infant | 4 | 2021 | 7946 | 0.080 |
Why?
| | Plethysmography | 1 | 2009 | 104 | 0.080 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 103 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2020 | 4631 | 0.080 |
Why?
| | Mitochondria | 1 | 2014 | 750 | 0.080 |
Why?
| | Calcinosis | 1 | 2011 | 242 | 0.080 |
Why?
| | Aspartate Aminotransferases | 1 | 2008 | 86 | 0.080 |
Why?
| | Ultrasonography | 2 | 2008 | 636 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2015 | 5040 | 0.070 |
Why?
| | Rats, Zucker | 1 | 2007 | 26 | 0.070 |
Why?
| | Parents | 1 | 2015 | 1190 | 0.070 |
Why?
| | Primary Health Care | 2 | 2018 | 1512 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 390 | 0.070 |
Why?
| | Thiazoles | 2 | 2019 | 110 | 0.070 |
Why?
| | PPAR alpha | 1 | 2007 | 52 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2011 | 342 | 0.070 |
Why?
| | Incidence | 3 | 2021 | 2318 | 0.070 |
Why?
| | Fenofibrate | 1 | 2007 | 24 | 0.070 |
Why?
| | Aged | 6 | 2022 | 19122 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2009 | 363 | 0.070 |
Why?
| | Forced Expiratory Volume | 2 | 2018 | 476 | 0.070 |
Why?
| | Thiazolidinediones | 1 | 2007 | 143 | 0.070 |
Why?
| | Random Allocation | 2 | 2021 | 336 | 0.070 |
Why?
| | Hyperlipidemias | 1 | 2007 | 122 | 0.070 |
Why?
| | Fatty Acid Synthases | 1 | 2006 | 23 | 0.070 |
Why?
| | Urban Population | 1 | 2008 | 401 | 0.060 |
Why?
| | Heart Rate | 1 | 2009 | 705 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2006 | 131 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2009 | 676 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2212 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 372 | 0.060 |
Why?
| | Coronary Artery Disease | 1 | 2011 | 608 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2019 | 477 | 0.060 |
Why?
| | Patient Selection | 1 | 2008 | 646 | 0.060 |
Why?
| | Motor Activity | 1 | 2009 | 642 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 35 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1715 | 0.060 |
Why?
| | Inflammation | 2 | 2018 | 2485 | 0.060 |
Why?
| | Flavonoids | 1 | 2004 | 68 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1127 | 0.060 |
Why?
| | Androstadienes | 1 | 2004 | 97 | 0.060 |
Why?
| | Cholesterol | 1 | 2005 | 368 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 928 | 0.060 |
Why?
| | Morpholines | 1 | 2004 | 102 | 0.060 |
Why?
| | Nuclear Family | 1 | 2023 | 49 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1355 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 276 | 0.050 |
Why?
| | Awareness | 1 | 2023 | 92 | 0.050 |
Why?
| | Malates | 1 | 2022 | 5 | 0.050 |
Why?
| | Fumarates | 1 | 2022 | 10 | 0.050 |
Why?
| | Carboxylic Acids | 1 | 2022 | 26 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 40 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 331 | 0.050 |
Why?
| | Phenylalanine | 1 | 2022 | 57 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 62 | 0.050 |
Why?
| | Off-Label Use | 1 | 2022 | 52 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 105 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2023 | 1184 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.050 |
Why?
| | Leucine | 1 | 2022 | 107 | 0.050 |
Why?
| | Glycine | 1 | 2022 | 153 | 0.050 |
Why?
| | Longevity | 1 | 2022 | 137 | 0.050 |
Why?
| | Liraglutide | 1 | 2021 | 27 | 0.050 |
Why?
| | Tryptophan | 1 | 2022 | 135 | 0.050 |
Why?
| | Bacteroidetes | 1 | 2021 | 20 | 0.050 |
Why?
| | Mutation | 2 | 2018 | 3350 | 0.050 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 752 | 0.050 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 257 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 71 | 0.050 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 6 | 0.050 |
Why?
| | Insulin Glargine | 1 | 2021 | 73 | 0.050 |
Why?
| | Wrist | 1 | 2021 | 48 | 0.050 |
Why?
| | Furosemide | 1 | 2020 | 32 | 0.050 |
Why?
| | Interleukin-18 | 1 | 2022 | 219 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 18 | 0.040 |
Why?
| | Counseling | 1 | 2023 | 342 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2106 | 0.040 |
Why?
| | Canada | 1 | 2021 | 322 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1857 | 0.040 |
Why?
| | Jet Lag Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 47 | 0.040 |
Why?
| | Research | 1 | 2022 | 395 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 748 | 0.040 |
Why?
| | Hyperuricemia | 1 | 2019 | 44 | 0.040 |
Why?
| | Carbon Isotopes | 1 | 2019 | 112 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 141 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 487 | 0.040 |
Why?
| | Cell Line | 1 | 2004 | 2645 | 0.040 |
Why?
| | Feces | 1 | 2021 | 373 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2006 | 2563 | 0.040 |
Why?
| | Wakefulness | 1 | 2019 | 128 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 35 | 0.040 |
Why?
| | Autoantigens | 1 | 2021 | 397 | 0.040 |
Why?
| | RNA | 1 | 2004 | 810 | 0.040 |
Why?
| | Ciprofloxacin | 1 | 1998 | 23 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2023 | 528 | 0.040 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 7 | 0.040 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 61 | 0.040 |
Why?
| | Cell Respiration | 1 | 2018 | 74 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 484 | 0.040 |
Why?
| | Fructokinases | 1 | 2018 | 29 | 0.040 |
Why?
| | Carbonated Beverages | 1 | 2018 | 15 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 746 | 0.040 |
Why?
| | Saliva | 1 | 2019 | 187 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 188 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 174 | 0.040 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 53 | 0.040 |
Why?
| | Communication | 1 | 2023 | 744 | 0.040 |
Why?
| | Vital Capacity | 1 | 2018 | 257 | 0.040 |
Why?
| | Proteome | 1 | 2021 | 339 | 0.040 |
Why?
| | Beverages | 1 | 2018 | 60 | 0.040 |
Why?
| | Mothers | 1 | 2023 | 652 | 0.040 |
Why?
| | Phosphorus Isotopes | 1 | 2017 | 8 | 0.040 |
Why?
| | Immunoconjugates | 1 | 1998 | 87 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2019 | 412 | 0.030 |
Why?
| | Postprandial Period | 1 | 2017 | 88 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 279 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2018 | 267 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 512 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1229 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 372 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 238 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2018 | 222 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 332 | 0.030 |
Why?
| | Deuterium | 1 | 2015 | 79 | 0.030 |
Why?
| | Stillbirth | 1 | 2015 | 57 | 0.030 |
Why?
| | Anti-Infective Agents | 1 | 1998 | 225 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 698 | 0.030 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 287 | 0.030 |
Why?
| | Graft Rejection | 1 | 1998 | 522 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2015 | 118 | 0.030 |
Why?
| | Insurance, Dental | 1 | 2014 | 11 | 0.030 |
Why?
| | Dental Care for Children | 1 | 2014 | 11 | 0.030 |
Why?
| | International Agencies | 1 | 2014 | 29 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 926 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 231 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2014 | 47 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1998 | 1042 | 0.030 |
Why?
| | Adolescent Medicine | 1 | 2014 | 33 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 182 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 476 | 0.030 |
Why?
| | Survival Rate | 1 | 2017 | 1646 | 0.030 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 127 | 0.030 |
Why?
| | Prenatal Care | 1 | 2015 | 254 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 184 | 0.030 |
Why?
| | Observer Variation | 1 | 2014 | 298 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 574 | 0.030 |
Why?
| | Mice | 2 | 2011 | 14927 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2018 | 373 | 0.030 |
Why?
| | Registries | 1 | 2020 | 1763 | 0.030 |
Why?
| | Insulin Infusion Systems | 1 | 2015 | 296 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 517 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 602 | 0.020 |
Why?
| | Intracellular Space | 1 | 2012 | 68 | 0.020 |
Why?
| | Patient Compliance | 1 | 2015 | 524 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1352 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 214 | 0.020 |
Why?
| | Signal Transduction | 1 | 2004 | 4525 | 0.020 |
Why?
| | Family | 1 | 2014 | 591 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 481 | 0.020 |
Why?
| | Diet | 1 | 2017 | 1076 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 608 | 0.020 |
Why?
| | Apoptosis | 1 | 1998 | 2366 | 0.020 |
Why?
| | Caregivers | 1 | 2014 | 712 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6357 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4718 | 0.010 |
Why?
| | Trazodone | 1 | 1998 | 2 | 0.010 |
Why?
| | Abatacept | 1 | 1998 | 40 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 1998 | 92 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1998 | 47 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 1998 | 54 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1998 | 79 | 0.010 |
Why?
| | CTLA-4 Antigen | 1 | 1998 | 78 | 0.010 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 1998 | 38 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1998 | 241 | 0.010 |
Why?
| | Cyclosporine | 1 | 1998 | 161 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1998 | 390 | 0.010 |
Why?
| | Antigens, CD | 1 | 1998 | 441 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 999 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1046 | 0.010 |
Why?
| | Drug Overdose | 1 | 1998 | 293 | 0.010 |
Why?
|
|
Nadeau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|